1 Min Read
Sept 5 (Reuters) - Novimmune SA (IPO-NOVI.S):
* RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR ITS LEAD DRUG EMAPALUMAB Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.